LUX-Lung 1 was a phase IIb/III study that looked at the benefit of Afatinib ( Giotrif ) and best supportive...
Afatinib ( Giotrif ) was compared with standard Platinum-based doublet chemotherapy in two large, randomized phase III studies, ie, LUX-Lung...
EGFR belongs to the ErbB family of transmembrane tyrosine kinase receptors ( ErbB comprises ErbB1/EGFR/HER1, ErbB2/HER2/NEU, ErbB3/HER3, and ErbB4/HER4 )....
Afatinib plus Paclitaxel versus chemotherapy in patients with metastatic non-small cell lung cancer progressed on Erlotinib / Gefitinib and Afatanib
Improved disease control with continuation of EGFR inhibition beyond progression has been suggested in retrospective / non-randomized studies, however, this...
Pooled analysis of LUX-Lung 3 and LUX-Lung 6 comparing Afatinib with chemotherapy: overall survival in patients with advanced non-small cell lung cancer harboring common EGFR mutations
Afatinib ( Giotrif ) is an oral, irreversible ErbB family blocker of EGFR, HER2, ErbB3 and ErbB4 signalling. LUX-Lung 3...
Giotrif for the treatment of EGFR TKI-naïve adult patients with locally advanced or metastatic non-small cell lung cancer with activating EGFR mutations
The Committee for Medicinal Products for Human Use ( CHMP ) has adopted a positive opinion, recommending the granting of...
- Gad Anxiety
- Gallbladder Disease
- Gardenia Extract
- Gastric Adenocarcinoma
- Gastric Cancer
- Gastrointestinal Bleeding
- Gastrointestinal Stromal Tumor
- Gastro-Oesophageal Junction Adenocarcinoma
- Gaucher Disease